Cipla Ltd.

Cipla is currently trading at Rs. 377.75, up by 2.40 points or 0.64% from its previous closing of Rs. 375.35 on the BSE.

The scrip opened at Rs. 375.50 and has touched a high and low of Rs. 380.00 and Rs. 374.45 respectively. So far 59627 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 435.00 on 09-Jan-2013 and a 52 week low of Rs. 300.70 on 12-Jun-2012.

Last one week high and low of the scrip stood at Rs. 403.40 and Rs. 364.05 respectively. The current market cap of the company is Rs. 30358.46 crore.

The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.08% and 28.32% respectively.

Cipla has granted the global commercialization rights for its nasal spray ‘Dymista’ to Swedish partner Meda AB except for certain geographies. The two companies have extended an existing partnership for development under which Meda will have full coverage in all growth markets in Latin and South America, West Asia and Africa and Asia, including more than 120 new markets for the nasal spray prescribed for allergic rhinitis.

Under their extended agreement, both partners will collaborate on follow-up compounds for Dymista, capitalizing on intellectual property retained by both partners. Cipla will be responsible for formulation, while Meda will be responsible for clinical development, registration, marketing and sales. The companies will also collaborate on future production of Dymista and any new products developed.

Dymista is a novel nasal treatment of allergic rhinitis. Dymista was approved in the US in May 2012 and in Europe in January 2013.